跳至主要内容
临床试验/EUCTR2016-003110-27-DK
EUCTR2016-003110-27-DK进行中(未招募)1 期

Bone turnover markers as predictors of treatment break outcome

Bente Lomholt Langdahl, Dept. of Endocrinology and Internal Medicine, Aarhus University Hospital0 个研究点目标入组 140 人开始时间: 2016年7月22日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
140

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Postmenopausal women (postmenopausal for at least two years)
  • Men above 50 years
  • Treatment for at least five years with alendronat
  • BMD T-score total hip > -2.5
  • BMD T-score lumbar spine (L1-L4) > -4
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 140
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 140

排除标准

  • Any low-energy fracture within the previous 5 years during
  • alendronat treatment (not including fingers, toes, or skull)
  • Low-energy vertebral fracture at any time
  • Low-energy hip fracture at any time
  • Ongoing treatment with glucocorticoids
  • Metabolic bone disease
  • Hormone replacement therapy
  • Other conditions affecting bone metabolism

研究者

发起方
Bente Lomholt Langdahl, Dept. of Endocrinology and Internal Medicine, Aarhus University Hospital

相似试验

Bone turnover markers as predictors of treatment... | 临床试验